Drug Profile
EXT 418
Alternative Names: EXT 418-ghrelin; EXT418; EXT418 - GhrelinLatest Information Update: 24 Nov 2022
Price :
$50
*
At a glance
- Originator Extend Biosciences
- Class Peptide hormones; Peptides
- Mechanism of Action Ghrelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cachexia
Highest Development Phases
- Preclinical Cachexia; Diabetic neuropathies
Most Recent Events
- 22 Nov 2022 EXT 418 is still in preclinical development in Cachexia in USA (Extend Biosciences pipeline, November 2022)
- 22 Nov 2022 Preclinical trials in Diabetic neuropathies in USA (IV) (Extend Biosciences pipeline, November 2022)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cachexia in USA (SC, Injection)